OC-0277 Interim safety analysis of RAPPORT trial - SABR with pembrolizumab in oligometastatic RCC. (April 2019) - Siva, S.; Bressel, M.; Sandhu, S.; Tran, B.; Mooi, J.; Lewin, J.; Loi, S.; Toner, G.; Moon, D.; Goad, J.; Shaw, M.; Chander, S.; et al.